What is Cardiosense?
Cardiosense operates at the intersection of clinical medicine and data science, developing a sophisticated digital biomarker platform. The company utilizes proprietary multi-sensor hardware and advanced algorithms to detect early-stage cardiac pathologies. By offering both a medical-grade wearable device and device-agnostic software, Cardiosense enables healthcare providers to aggregate and analyze complex physiological waveforms with unprecedented precision.
The firm's core competency lies in its application of deep learning to raw physiological data, facilitating a shift toward personalized, proactive cardiac care. This technological stack is designed to integrate seamlessly into existing clinical workflows, providing practitioners with actionable insights that improve patient outcomes while optimizing the efficiency of cardiac care delivery.
How much funding has Cardiosense raised?
Cardiosense has raised a total of $41.2M across 1 funding round:
Series A
$15.1M
Series A (2022): $15.1M with participation from UnityPoint Health Ventures, Hatteras Venture Partners, Portal Innovations, OSF Ventures, Broadview Ventures, and Laerdal Million Lives Fund
Key Investors in Cardiosense
UnityPoint Health Ventures
The venture capital arm of a major integrated health system, focusing on investments that improve patient outcomes and reduce healthcare costs.
Hatteras Venture Partners
A venture capital firm specializing in building transformative companies within the biotech, MedTech, and HealthTech sectors.
Portal Innovations
A venture development engine and life sciences firm providing crafted capital and lab infrastructure to early-stage biotech and medtech startups.
What's next for Cardiosense?
With the recent capital deployment, Cardiosense is expected to focus on scaling its clinical AI capabilities and broadening its market reach. The strategic backing from specialized healthcare investors suggests a roadmap centered on regulatory milestones and the expansion of its diagnostic ecosystem. As the company transitions from development to commercial maturity, the focus will likely shift toward large-scale clinical validation and the integration of its platform into major health systems.
The firm's ability to maintain its competitive edge will depend on its continued innovation in sensor technology and the robustness of its proprietary algorithms. By addressing the critical need for early detection in cardiovascular health, Cardiosense is well-positioned to capture significant market share in the evolving digital health sector.
